Stefano Omboni1, Ettore Malacco2, Claudio Napoli3,4, Pietro Amedeo Modesti5, Athanasios Manolis6, Gianfranco Parati7,8, Enrico Agabiti-Rosei9, Claudio Borghi10. 1. Clinical Research Unit, Italian Institute of Telemedicine, Varese, Italy. stefano.omboni@iitelemed.org. 2. L. Sacco Hospital, Milan, Italy. 3. Department of Internal Medicine and Specialistic Units, U.O.C. of Clinical Immunology, Immunohematology, Transfusion Medicine and Organ Transplantation, Azienda Ospedaliera Universitaria (AOU), Second University of Naples, Naples, Italy. 4. SDN Foundation and IRCCS, Naples, Italy. 5. Department of Clinical and Experimental Medicine, Careggi Hospital, University of Florence, Florence, Italy. 6. Asklepeion General Hospital of Voula, University of Athens, Athens, Greece. 7. Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, Milan, Italy. 8. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. 9. Division of Medicine and Surgery, Spedali Civili and University of Brescia, Brescia, Italy. 10. Department of Internal Medicine, University of Bologna, Bologna, Italy.
Erratum to: Adv Ther (2017) 34:784–798 DOI 10.1007/s12325-017-0497-8
Author wants to correct the text under the heading of Introduction.The sentence is written as:“In the ZENITH study, both treatments had a similar positive effect on regression of cardiac and renal damage, whereas a larger proportion of patients showing carotid plaque regression was observed under zofenopril (31.6% vs. 16.1%; p = 0.047), particularly in the subgroup of patients taking the low dose of zofenopril (30 mg) plus HCTZ 12.5 mg (4.7% vs 10.0% irbesartan 150 mg plus HCTZ 12.5 mg; p = 0.043)”.The correct sentence should read:“In the ZENITH study, both treatments had a similar positive effect on regression of cardiac and renal damage, whereas a larger proportion of patients showing carotid plaque regression was observed under zofenopril (31.6% vs. 16.1%; p = 0.047). Interestingly, in the subgroup of patients taking the low dose of zofenopril (30 mg) plus HCTZ 12.5 mg the rate of those exhibiting a carotid plaque at study end was significantly lower than that in the subgroup of patients taking the low dose of irbesartan (150 mg) plus HCTZ 12.5 mg (4.7% vs 10.0%; p = 0.043)”.